Allergan's Avycaz gets Priority Review

In October, FDA accepted and granted Priority Review to an sNDA from Allergan plc (NYSE:AGN) for Avycaz ceftazidime/avibactam (CAZ-104) to treat hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) in adults. FDA's decision is expected next quarter.

Avycaz is already approved in the U.S. to treat complicated intra-abdominal infections (cIAI) in combination with metronidazole, and complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible Gram-negative bacteria (see BioCentury, Feb. 2)...